Sorted By Test Name - Mayo Medical Laboratories

TAE
82977
TAMV
82514
Toxic concentration: > or =20.0 mcg/mL
Clinical References: 1. Pesce AJ, Rashkin M, Kotagal U: Standards of laboratory practice:
theophylline and caffeine monitoring. Clin Chem 1998, May;44(5);1124-1128 2. McCudden CR,
Broussard LA: Caffeine, lithium and theophylline. In Therapeutic Drug Monitoring Data: A Concise
Guide, 3rd edition, Edited by CA Hammett-Stabler, A Dasgupta, AACC Press, 2007 3. Vassallo R,
Lipsky JJ: Theophylline: recent advances in the understanding of its mode of action and uses in clinical
practice. Mayo Clin Proc 1998;73:346-354
Therapeutic Antibody by Flow Cytometry
Clinical Information: Monoclonal antibodies are critical tools for detecting cellular antigens in
various hematologic diseases and are used to provide critical diagnostic information. Monoclonal
antibodies are also used as therapeutic agents in a variety of hematologic diseases. For example,
anti-CD20 antibodies have been used to treat patients with B-cell malignant lymphomas and multiple
myeloma. Other examples include: -Anti-CD52 (Campath-1H): B-cell chronic lymphocytic leukemia and
T-cell disorders -Anti-CD3 and T-cell malignancies -Anti-CD33: acute myeloid leukemia This list will
undoubtedly expand over time to include other antibodies. It may be necessary to document expression of
these markers by the malignant cells prior to initiating the respective monoclonal antibody therapy.
Expression of these markers may also be required for follow-up to monitor the impact of treatment on
residual normal counterparts (eg, CD20-positive lymphocytes in patients treated with anti-CD20).
Useful For: Detecting cell-surface antigens on malignant cells that are potential therapeutic antibody
targets Determining the eligibility of patients for monoclonal antibody therapies Monitoring response to
the therapeutic antibody
Interpretation: The immunophenotyping report will summarize the pattern of antigenic expression on
malignant cells and, if necessary, the normal cellular counterpart(s) that correspond to the therapeutic
monoclonal antibody target.
Reference Values:
Normal individuals have B-lymphocytes, T-lymphocytes, or myeloid cells that express the corresponding
cell-surface antigen(s) in question.
Clinical References: 1. Davis AT: Monoclonal antibody-based therapy of lymphoid neoplasms:
what's on the horizon? Semin Hematol 2000;37(4 Suppl 7):34-42 2. Czuczman MS, Grillo-Lopez AJ,
White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric
anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276 3. Flynn JM,
Byrd JC: Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000;12:574-581 4. Kreitman RJ,
Wilson WH, Bergeron K, et al: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in
chemotherapy-resistant hairy-cell leukemia. N Eng J Med 2001;345:241-247 5. van der Velden VH, te
Marvelde JG, Hoogeveen PG, et al: Targeting of the CD33-calicheamicin immunoconjugate Mylotarg
(CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and
normal myeloid cells. Blood 2001;97:3197-3204
Thermoactinomyces vulgaris, IgG Antibodies, Serum
Clinical Information: Thermoactinomyces vulgaris is a causative agent of hypersensitivity
pneumonitis (HP). Other causative microorganisms include Micropolyspora faeni and Aspergillus
fumigatus. While the immunopathogenesis of HP is not known, several immune mechanisms are
postulated to play a role, including both cellular and humoral mechanisms.(1)
Useful For: Evaluating patients suspected of having hypersensitivity pneumonitis induced by exposure
to this antigen
Interpretation: Elevated concentrations of IgG antibodies to Thermoactinomyces vulgaris are
consistent with the diagnosis of hypersensitivity pneumonitis (HP) caused by exposure to this antigen.
Elevated concentrations of IgG antibodies to Thermoactinomyces vulgaris were found in a small number
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1725